EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Design of a Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Nipocalimab in Pregnancies at Risk for Fetal and Neonatal Alloimmune Thrombocytopenia

Heidi Tiller iD, Eleonor Tiblad, Pamela Baker, Hillary Van Valkenburgh, Dirk Heerwegh, Babajide Keshinro

American Journal of Perinatology · 01.04.2026 · 43 (05) · 648-656

DOI: 10.1055/a-2666-5642 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Perinatology, erschienen am 01.04.2026. Verfasst von Heidi Tiller und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway. Hauptthemen laut MEDLINE: Thrombocytopenia, Neonatal Alloimmune, Antibodies, Monoclonal, Humanized, Fetal Diseases. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Johnson & Johnson.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nipocalimab, a neonatal Fc receptor blocker, inhibits transplacental transfer of maternal immunoglobulin G (IgG) and lowers circulating maternal IgG levels. In a phase 2 study, nipocalimab demonstrated evidence of safety and efficacy in delaying or preventing fetal anemia in early-onset severe hemolytic disease of the fetus and newborn, suggesting a potential benefit in other IgG alloantibody-mediated perinatal diseases, including fetal and neonatal alloimmune thrombocytopenia (FNAIT). The phase 3 FREESIA-1 study aims to evaluate the safety and efficacy of nipocalimab in at-risk FNAIT pregnancies. This multicenter, placebo-controlled, double-blind, phase 3 study will enroll human platelet antigen (HPA)-1a-alloimmunized pregnant individuals with an HPA-1a-positive fetus and prior FNAIT-affected pregnancy without intracranial hemorrhage or severe bleeding in the fetus/newborn. Participants will be randomized 2:1 to weekly intravenous nipocalimab or placebo at 13 to 18 weeks of gestation until delivery. Maternal participants will receive ultrasound monitoring approximately every 2 weeks during treatment. Neonates will receive a cranial ultrasound scan, platelet count assessment, and, if needed, platelet transfusion. Maternal participants will be followed for 24 weeks and neonates/infants for 104 weeks. The primary endpoint is an adverse outcome of fetal death or adjudicated severe bleeding in utero up to 1 week postbirth, or neonatal platelet count at birth < 30 × 109/L. Key secondary endpoints include adjudicated bleeding in utero up to the first week postbirth in fetuses/neonates and platelet count at birth in neonates. Additional secondary endpoints in fetuses/neonates include death; platelet count at birth

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thrombocytopenia, Neonatal AlloimmuneAntibodies, Monoclonal, HumanizedFetal DiseasesHumansFemalePregnancyDouble-Blind MethodInfant, NewbornRandomized Controlled Trials as TopicMulticenter Studies as TopicAntigens, Human PlateletAdultClinical Trials, Phase III as Topic

Substanzen

Antibodies, Monoclonal, HumanizedAntigens, Human Platelet

Autor:innen und Institutionen

  • Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway.
  • Department of Obstetrics and Gynecology, University Hospital of North Norway, Tromsø, Norway.
  • Clinical Epidemiology Division, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden.
  • Johnson & Johnson, Spring House, Pennsylvania.
  • Johnson & Johnson, Beerse, Belgium.
  • Johnson & Johnson, Biologics BV, Leiden, The Netherlands.

ORCID-Profile: Heidi Tiller

Förderung

  • Johnson & Johnson

Zitieren

APA

Tiller, H., Tiblad, E., Baker, P., Van Valkenburgh, H., Heerwegh, D., & Keshinro, B. (2026). Design of a Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Nipocalimab in Pregnancies at Risk for Fetal and Neonatal Alloimmune Thrombocytopenia. American Journal of Perinatology, 43(05), 648-656. https://doi.org/10.1055/a-2666-5642

Vancouver

Tiller H, Tiblad E, Baker P, Van Valkenburgh H, Heerwegh D, Keshinro B. Design of a Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Nipocalimab in Pregnancies at Risk for Fetal and Neonatal Alloimmune Thrombocytopenia. American Journal of Perinatology. 2026;43(05):648-656. doi:10.1055/a-2666-5642

BibTeX
@article{Tiller2026,
  author = {Tiller, Heidi and Tiblad, Eleonor and Baker, Pamela and Van Valkenburgh, Hillary and Heerwegh, Dirk and Keshinro, Babajide},
  title = {Design of a Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Nipocalimab in Pregnancies at Risk for Fetal and Neonatal Alloimmune Thrombocytopenia},
  journal = {American Journal of Perinatology},
  year = {2026},
  volume = {43},
  number = {05},
  pages = {648--656},
  doi = {10.1055/a-2666-5642}
}
Kostenlos starten →